Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.59 |
| ▸ | DRD4 | P21917 | 3/20 | 0.56 |
| ▸ | DRD3 | P35462 | 2/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 2/20 | 0.52 |
| ▸ | MLNR | O43193 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | CCR3 | P51677 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12385826 | 0.92 | MLNR (0.53) | ACHEDRD4DRD3DRD2CHRM3 | |
| SCHEMBL28024099 | 0.86 | FAAH (0.63) | DRD4DRD3DRD2CHRM3HRH3 | |
| SCHEMBL20804353 | 0.86 | FAAH (0.63) | DRD4DRD3DRD2CHRM3HRH3 | |
| SCHEMBL12533594 | 0.85 | DRD4 (0.53) | DRD4DRD3DRD2CHRM3MLNR | |
| SCHEMBL12384476 | 0.85 | DRD4 (0.53) | DRD4DRD3DRD2CHRM3MLNR | |
| SCHEMBL12518834 | 0.83 | PDE2A (0.55) | DRD3DRD2MLNRHRH3ROCK2 | |
| SCHEMBL2227448 | 0.83 | HRH3 (0.60) | HRH3FAAH | |
| SCHEMBL27912351 | 0.83 | FAAH (0.56) | DRD4DRD3DRD2CHRM3HRH3 | |
| SCHEMBL29678370 | 0.83 | HRH3 (0.60) | HRH3FAAH | |
| SCHEMBL29809149 | 0.82 | HRH3 (0.60) | DRD4DRD3DRD2HRH3FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181183-B2 | Prostaglandin D synthase inhibitory piperidine compounds | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| US-9181183-B2 | Prostaglandin D synthase inhibitory piperidine compounds | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| EP-2615084-A1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | Taiho Pharmaceutical Co., Ltd. (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-20130165438-A1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-27 | — | — | US | disclosed |
| US-20130165438-A1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-27 | — | — | US | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8252814-B2 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252814-B2 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-28 | — | — | US | disclosed |
| WO-2012033069-A1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | 大鵬薬品工業株式会社 (JP) | 2012-03-15 | — | — | WO | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISHIHARA YUJI | 2009-10-22 | — | — | US | disclosed |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISHIHARA YUJI | 2009-10-22 | — | — | US | disclosed |
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | ACHE 1/4885DRD4 3327/4885DRD3 2768/4885 |
| US-20130165438-A1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | PTGIS, PTGS1, PTGDR | ACHE 1060/4885DRD4 260/4885DRD3 186/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | ACHE 3858/4885DRD4 3211/4885DRD3 3022/4885 |
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | CXCR4, CXCR1, CXCR3 | ACHE 3909/4885DRD4 1261/4885DRD3 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.